High Permissiveness for Genetic Exchanges between Enteroviruses of Species A, including Enterovirus 71, Favors Evolution through Intertypic Recombination in Madagascar.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
15 03 2019
Historique:
received: 23 09 2018
accepted: 18 12 2018
pubmed: 4 1 2019
medline: 20 11 2019
entrez: 4 1 2019
Statut: epublish

Résumé

Human enteroviruses of species A (EV-A) are the leading cause of hand-foot-and-mouth disease (HFMD). EV-A71 is frequently implicated in HFMD outbreaks and can also cause severe neurological manifestations. We investigated the molecular epidemiological processes at work and the contribution of genetic recombination to the evolutionary history of EV-A in Madagascar, focusing on the recently described EV-A71 genogroup F in particular. Twenty-three EV-A isolates, collected mostly in 2011 from healthy children living in various districts of Madagascar, were characterized by whole-genome sequencing. Eight different types were identified, highlighting the local circulation and diversity of EV-A. Comparative genome analysis revealed evidence of frequent recent intra- and intertypic genetic exchanges between the noncapsid sequences of Madagascan EV-A isolates. The three EV-A71 isolates had different evolutionary histories in terms of recombination, with one isolate displaying a mosaic genome resulting from recent genetic exchanges with Madagascan coxsackieviruses A7 and possibly A5 and A10 or common ancestors. The engineering and characterization of recombinants generated from progenitors belonging to different EV-A types or EV-A71 genogroups with distantly related nonstructural sequences indicated a high level of permissiveness for intertypic genetic exchange in EV-A. This permissiveness suggests that the primary viral functions associated with the nonstructural sequences have been highly conserved through the diversification and evolution of the EV-A species. No outbreak of disease due to EV-A has yet been reported in Madagascar, but the diversity, circulation, and evolution of these viruses justify surveillance of EV-A circulation and HFMD cases to prevent possible outbreaks due to emerging strains.

Identifiants

pubmed: 30602612
pii: JVI.01667-18
doi: 10.1128/JVI.01667-18
pmc: PMC6401452
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 American Society for Microbiology.

Références

Microbiol Mol Biol Rev. 2014 Jun;78(2):278-303
pubmed: 24847023
Lancet Infect Dis. 2010 Nov;10(11):778-90
pubmed: 20961813
Infect Genet Evol. 2013 Mar;14:282-93
pubmed: 23201849
J Med Virol. 2012 Apr;84(4):624-31
pubmed: 22337302
J Clin Virol. 2015 Sep;70:29-38
pubmed: 26305816
J Gen Virol. 2016 Dec;97(12):3225-3231
pubmed: 27692044
J Gen Virol. 2015 May;96(Pt 5):1067-1079
pubmed: 25614593
J Virol. 1999 Oct;73(10):8741-9
pubmed: 10482628
J Virol. 2003 Oct;77(19):10423-31
pubmed: 12970427
J Gen Virol. 2002 Sep;83(Pt 9):2193-2200
pubmed: 12185273
J Clin Microbiol. 2012 May;50(5):1650-8
pubmed: 22337981
Int J Med Microbiol. 2015 Oct;305(7):601-6
pubmed: 26321005
J Clin Microbiol. 2013 Mar;51(3):759-70
pubmed: 23254123
J Clin Microbiol. 2005 Jan;43(1):242-9
pubmed: 15634978
Front Microbiol. 2018 Sep 28;9:2339
pubmed: 30323802
Nat Methods. 2012 Jul 30;9(8):772
pubmed: 22847109
Viruses. 2011 Aug;3(8):1460-84
pubmed: 21994791
Emerg Microbes Infect. 2018 Jun 21;7(1):111
pubmed: 29930332
J Virol. 2005 Oct;79(20):12650-7
pubmed: 16188967
Sci Rep. 2016 Dec 13;6:38831
pubmed: 27958320
Rev Med Virol. 2005 May-Jun;15(3):157-67
pubmed: 15578739
mBio. 2014 Aug 05;5(4):e01119-14
pubmed: 25096874
J Virol. 2013 May;87(9):4907-22
pubmed: 23408630
PLoS Pathog. 2014 Jun 12;10(6):e1004191
pubmed: 24945141
Virus Evol. 2015 May 26;1(1):vev003
pubmed: 27774277
J Virol. 2003 Aug;77(16):8973-84
pubmed: 12885914
J Gen Virol. 2011 Jun;92(Pt 6):1380-1390
pubmed: 21346025
J Virol. 2001 Aug;75(16):7732-8
pubmed: 11462047
Euro Surveill. 2017 Jun 29;22(26):
pubmed: 28681718
J Virol. 1999 Jan;73(1):152-60
pubmed: 9847317
Euro Surveill. 2015;20(34):30005
pubmed: 26530407
J Clin Microbiol. 2009 Sep;47(9):2826-33
pubmed: 19625480
Genome Announc. 2014 Jun 19;2(3):
pubmed: 24948760
BMC Evol Biol. 2007 Nov 08;7:214
pubmed: 17996036
J Infect Dis. 2012 May 1;205(9):1363-73
pubmed: 22457288
PLoS One. 2014 Mar 05;9(3):e90624
pubmed: 24598878
Euro Surveill. 2014 Apr 17;19(15):
pubmed: 24762664
Clin Infect Dis. 2015 Mar 1;60(5):797-803
pubmed: 25352588
Emerg Infect Dis. 2015 Jan;21(1):123-6
pubmed: 25531549
Virus Res. 2008 Feb;131(2):250-9
pubmed: 18036697
J Virol. 2006 Jan;80(1):483-93
pubmed: 16352572
Mol Biol Evol. 2013 Dec;30(12):2725-9
pubmed: 24132122
Syst Biol. 2003 Oct;52(5):696-704
pubmed: 14530136
J Gen Virol. 2010 Sep;91(Pt 9):2263-77
pubmed: 20505012
Emerg Infect Dis. 2016 Apr;22(4):753-5
pubmed: 26982072
J Virol. 2012 Mar;86(5):2676-85
pubmed: 22205739
Emerg Microbes Infect. 2016 Sep 21;5(9):e104
pubmed: 27651091
J Gen Virol. 2014 Apr;95(Pt 4):868-873
pubmed: 24425417
J Gen Virol. 2001 Jan;82(Pt 1):79-91
pubmed: 11125161
PLoS One. 2011;6(9):e24823
pubmed: 21931857
J Gen Virol. 2004 Jun;85(Pt 6):1597-1607
pubmed: 15166444
J Clin Microbiol. 2011 Jul;49(7):2426-34
pubmed: 21543560
J Virol Methods. 2012 Dec;186(1-2):104-8
pubmed: 22939977
PLoS Pathog. 2007 Dec;3(12):e191
pubmed: 18085822
J Gen Virol. 2006 Jan;87(Pt 1):119-28
pubmed: 16361424
J Virol Methods. 2012 Oct;185(1):142-8
pubmed: 22766179
Clin Microbiol Infect. 2012 May;18(5):E110-8
pubmed: 22404077
J Virol. 1999 Mar;73(3):1941-8
pubmed: 9971773
Virus Evol. 2018 Jul 13;4(2):vey020
pubmed: 30026965
Mol Biol Evol. 2005 May;22(5):1185-92
pubmed: 15703244
BMC Microbiol. 2006 Aug 30;6:74
pubmed: 16939656
J Clin Microbiol. 2008 Oct;46(10):3192-200
pubmed: 18650362
Infect Genet Evol. 2011 Jul;11(5):886-94
pubmed: 21352955
Proc Natl Acad Sci U S A. 2007 May 29;104(22):9457-62
pubmed: 17517601
Emerg Infect Dis. 2013 Jun;19(6):1008-10
pubmed: 23735779
Emerg Microbes Infect. 2018 Jan 24;7(1):8
pubmed: 29362406
PLoS Pathog. 2009 May;5(5):e1000412
pubmed: 19412342
PLoS Pathog. 2015 Nov 12;11(11):e1005266
pubmed: 26562151
Syst Biol. 2010 May;59(3):307-21
pubmed: 20525638

Auteurs

Romain Volle (R)

Institut Pasteur, Unité de Biologie des Virus Entériques, Paris, France.
INSERM U994, Institut National de la Santé et de la Recherche Médicale, Paris, France.

Richter Razafindratsimandresy (R)

Institut Pasteur de Madagascar, Antananarivo, Madagascar.

Marie-Line Joffret (ML)

Institut Pasteur, Unité de Biologie des Virus Entériques, Paris, France.
INSERM U994, Institut National de la Santé et de la Recherche Médicale, Paris, France.

Maël Bessaud (M)

Institut Pasteur, Unité de Biologie des Virus Entériques, Paris, France.
INSERM U994, Institut National de la Santé et de la Recherche Médicale, Paris, France.

Sendraharimanana Rabemanantsoa (S)

Institut Pasteur de Madagascar, Antananarivo, Madagascar.

Seta Andriamamonjy (S)

Institut Pasteur de Madagascar, Antananarivo, Madagascar.

Jonhson Raharinantoanina (J)

Institut Pasteur de Madagascar, Antananarivo, Madagascar.

Bruno Blondel (B)

Institut Pasteur, Unité de Biologie des Virus Entériques, Paris, France.
INSERM U994, Institut National de la Santé et de la Recherche Médicale, Paris, France.

Jean-Michel Heraud (JM)

Institut Pasteur de Madagascar, Antananarivo, Madagascar.

Jean-Luc Bailly (JL)

Université Clermont Auvergne, CNRS, LMGE, Clermont-Ferrand, France.

Francis Delpeyroux (F)

Institut Pasteur, Unité de Biologie des Virus Entériques, Paris, France francis.delpeyroux@pasteur.fr.
INSERM U994, Institut National de la Santé et de la Recherche Médicale, Paris, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH